6 Andriole GL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.
7 Shoag JE, Mittal S, Hu JC. Reevaluating PSA Testing Rates in the PLCO Trial. N Engl J Med. 2016;374(18):1795–6.
8 Ilic D, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362: p. k3519.
9 Roobol MJ, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2009;56(4):584–91.
10 Randazzo M, et al. A “PSA Pyramid” for Men with Initial Prostate-specific Antigen </=3 ng/ml: A Plea for Individualized Prostate Cancer Screening. Eur Urol, 2014.
11. Randazzo M, et al. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). BJU Int. 2016;117(4):576–83.
12 Randazzo M, et al. Is further screening of men with baseline PSA <1 ng ml(-1) worthwhile? The discussion continues – Results of the Swiss ERSPC (Aarau). Int J Cancer. 2015;137(3):553–9.
13 Schroder FH, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.